Generic Name and Formulations:
Cosyntropin 0.25mg/mL; pwd for IV or IM inj after reconstitution; preservative-free.
Amphastar Pharmaceuticals, Inc.
Indications for CORTROSYN:
For use in the screening of patients presumed to have adrenocortical insufficiency.
Adults and Children:
Give by IV, IM inj or IV infusion over 4–8hrs. <2yrs: 0.125mg. ≥2yrs: Usual range: 0.25–0.75mg.
Patients with raised bilirubin or where plasma contains free hemoglobin: falsely high fluorescence measurements may result. Pregnancy (Cat.C). Nursing mothers.
May accentuate the electrolyte loss associated with diuretics. May exhibit abnormally high plasma cortisol levels if patients taking cortisone, hydrocortisone, spironolactone, estrogens.
Hypersensitivity reactions (eg, rare, but possible), bradycardia, tachycardia, hypertension, peripheral edema, rash.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Travel Distance to Prostate Cancer Treatment Influences Treatment Choice
- Sexual Aids and Resources Not Readily Available at Cancer Centers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|